JP2011520959A - 新規可溶性ｃｄ８３ポリペプチド、配合物および使用法 - Google Patents

新規可溶性ｃｄ８３ポリペプチド、配合物および使用法 Download PDF

Info

Publication number
JP2011520959A
JP2011520959A JP2011510515A JP2011510515A JP2011520959A JP 2011520959 A JP2011520959 A JP 2011520959A JP 2011510515 A JP2011510515 A JP 2011510515A JP 2011510515 A JP2011510515 A JP 2011510515A JP 2011520959 A JP2011520959 A JP 2011520959A
Authority
JP
Japan
Prior art keywords
seq
amino acid
hcd83ext
polypeptide
scd83
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011510515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520959A5 (enExample
Inventor
ブランド，スティーヴン
シュー，チィ−シュン
ムー−ヤン，マレー
Original Assignee
アルゴス・セラピューティクス・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルゴス・セラピューティクス・インコーポレーテッド filed Critical アルゴス・セラピューティクス・インコーポレーテッド
Publication of JP2011520959A publication Critical patent/JP2011520959A/ja
Publication of JP2011520959A5 publication Critical patent/JP2011520959A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
JP2011510515A 2008-05-23 2009-05-22 新規可溶性ｃｄ８３ポリペプチド、配合物および使用法 Pending JP2011520959A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12870908P 2008-05-23 2008-05-23
US61/128,709 2008-05-23
PCT/US2009/003174 WO2009142759A1 (en) 2008-05-23 2009-05-22 Novel soluble cd83 polypeptides, formulations and methods of use

Publications (2)

Publication Number Publication Date
JP2011520959A true JP2011520959A (ja) 2011-07-21
JP2011520959A5 JP2011520959A5 (enExample) 2012-07-05

Family

ID=41340432

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011510515A Pending JP2011520959A (ja) 2008-05-23 2009-05-22 新規可溶性ｃｄ８３ポリペプチド、配合物および使用法

Country Status (12)

Country Link
US (1) US20110182903A1 (enExample)
EP (1) EP2288387B1 (enExample)
JP (1) JP2011520959A (enExample)
KR (2) KR101679084B1 (enExample)
CN (1) CN102036690B (enExample)
AU (1) AU2009249540B9 (enExample)
BR (1) BRPI0913577B1 (enExample)
CA (1) CA2725198A1 (enExample)
IL (1) IL209207A (enExample)
MX (1) MX2010012576A (enExample)
RU (1) RU2535340C2 (enExample)
WO (1) WO2009142759A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019515888A (ja) * 2017-04-01 2019-06-13 エーブイエム・バイオテクノロジー・エルエルシー 細胞免疫療法前の細胞毒性プレコンディショニングの代替
JP2023522022A (ja) * 2020-04-16 2023-05-26 フリードリッヒ‐アレクサンダー‐ウニフェルジテート エアランゲン‐ニュルンベルク 創傷治癒、発毛、ならびにスキンケアおよびヘアケアのためのｓＣＤ８３

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1422241A1 (en) 2002-11-19 2004-05-26 Alexander Steinkasserer Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases
US9102726B2 (en) * 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
US7169898B2 (en) 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
CN103243119B (zh) * 2013-05-20 2016-03-30 中国科学技术大学 可溶性cd83的表达和制备方法
US20190315878A1 (en) 2016-11-07 2019-10-17 Argos Therapeutics Inc. Bispecific antibodies that modulate tlr-4 signaling and uses thereof
KR102282341B1 (ko) 2018-09-12 2021-07-27 아주대학교산학협력단 Cd83 억제제를 유효성분으로 포함하는 베체트병의 예방 또는 치료용 조성물
DE102024110866A1 (de) 2024-04-18 2025-10-23 Christian Arnold Pharmazeutische Zusammensetzung zur Heilung einer Wunde

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006523432A (ja) * 2002-11-19 2006-10-19 アルゴス セラピューティクス，インコーポレイティド 疾患の治療または予防のための可溶型ｃｄ８３タンパク質およびそれをコードする核酸の使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5316920A (en) * 1992-04-17 1994-05-31 Dana-Faber Cancer Institute, Inc. Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily
US5710262A (en) * 1992-04-17 1998-01-20 Dana-Faber Cancer Institute, Inc. Nucleic acid encoding HB15 polypeptides
KR20010023325A (ko) * 1997-08-26 2001-03-26 리스 데브라 케이. 함지방세포-특이적 단백질 상동체
PT1223971E (pt) 1999-10-27 2005-10-31 Alexandra Lucas Composicoes e metodos para prevencao e tratamento da rejeicao de transplante
US20020014242A1 (en) * 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
US20040185040A1 (en) * 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
US20030219436A1 (en) * 2002-03-15 2003-11-27 Ledbetter Jeffrey A. Compositions and methods to regulate an immune response using CD83 gene expressed in tumors and using soluble CD83-Ig fusion protein
EP1578366A4 (en) * 2002-10-09 2007-12-19 Tolerrx Inc MOLECULES PREFERABLY ASSOCIATED WITH EFFECTOR T CELLS OR REGULATORY T CELLS AND METHODS OF USE THEREOF
US9102726B2 (en) 2002-12-04 2015-08-11 Argos Therapeutics, Inc. Nucleic acid of recombination expression vector encoding soluble forms of CD83, host cells transformed/transfected therewith and pharmaceutical compositions containing same
US7169898B2 (en) * 2002-12-04 2007-01-30 Alexander Steinkasserer Soluble CD83 proteins and use thereof for the treatment or prevention of a disease or medical condition caused by dysfunction or undesired function of a cellular immune response involving T cells
EP2789625B1 (en) * 2006-08-18 2018-06-06 Argos Therapeutics, Inc. Use of soluble CD83 for perfusing a tissue for transplantation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006523432A (ja) * 2002-11-19 2006-10-19 アルゴス セラピューティクス，インコーポレイティド 疾患の治療または予防のための可溶型ｃｄ８３タンパク質およびそれをコードする核酸の使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5011002484; ＯＨＴＡ，　Ｙ．　ｅｔ　ａｌ．: '"ＨＯＭＯＬＯＧＳ　ＯＦ　ＣＤ８３　ＦＲＯＭ　ＥＬＡＳＭＯＢＲＡＮＣＨ　ＡＮＤ　ＴＥＬＥＯＳＴ　ＦＩＳＨ．"' ＴＨＥ　ＪＯＵＲＮＡＬ　ＯＦ　ＩＭＭＵＮＯＬＯＧＹ Ｖｏｌ．１７３，　Ｎｏ．７, 200410, Ｐ．４５５３-４５６０ *
JPN5011002485; ＺＩＮＳＥＲ，　Ｅ．　ｅｔ　ａｌ．: '"Ｄｅｔｅｒｍｉｎａｔｉｏｎ　ｏｆ　ｔｈｅ　ｉｎｈｉｂｉｔｏｒｙ　ａｃｔｉｖｉｔｙ　ａｎｄ　ｂｉｏｌｏｇｉｃａｌ　ｈａｌｆ-ｌｉｖｅ　ｏｆ　ｓｏｌｕｂｌｅ　ＣＤ８３：　ｃｏｍｐａｒｉｓｏｎ　ｏｆ　ｗｉ' ＩＭＭＵＮＯＢＩＯＬＯＧＹ Ｖｏｌ．２１１，　Ｎｏ．６-８, 2006, Ｐ．４４９-４５３ *
JPN6013062918; ＬＥＣＨＭＡＮＮ，　Ｍ．　ｅｔ　ａｌ．: '"ＣＤ８３　ｉｓ　ａ　ｄｉｍｅｒ：　Ｃｏｍｐａｒａｔｉｖｅ　ａｎａｌｙｓｉｓ　ｏｆ　ｍｏｎｏｍｅｒｉｃ　ａｎｄ　ｄｉｍｅｒｉｃ　ｉｓｏｆｏｒｍｓ．"' ＢＩＯＣＨＥＭＩＣＡＬ　ＡＮＤ　ＢＩＯＰＨＹＳＩＣＡＬ　ＲＥＳＥＡＲＣＨ　ＣＯＭＭＵＮＩＣＡＴＩＯＮＳ Ｖｏｌ．３２９，　Ｎｏ．１, 20050401, Ｐ．１３２-１３９ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019515888A (ja) * 2017-04-01 2019-06-13 エーブイエム・バイオテクノロジー・エルエルシー 細胞免疫療法前の細胞毒性プレコンディショニングの代替
US11219628B2 (en) 2017-04-01 2022-01-11 Avm Biotechnology, Llc Replacement of cytotoxic preconditioning before cellular immunotherapy
JP2023522022A (ja) * 2020-04-16 2023-05-26 フリードリッヒ‐アレクサンダー‐ウニフェルジテート エアランゲン‐ニュルンベルク 創傷治癒、発毛、ならびにスキンケアおよびヘアケアのためのｓＣＤ８３

Also Published As

Publication number Publication date
AU2009249540B9 (en) 2014-09-18
EP2288387A4 (en) 2011-04-27
CN102036690B (zh) 2013-11-06
KR20110018381A (ko) 2011-02-23
CA2725198A1 (en) 2009-11-26
RU2010152553A (ru) 2012-06-27
AU2009249540A8 (en) 2011-01-20
BRPI0913577B1 (pt) 2022-05-31
KR20160104101A (ko) 2016-09-02
HK1155066A1 (en) 2012-05-11
EP2288387B1 (en) 2013-02-13
AU2009249540A1 (en) 2009-11-26
RU2535340C2 (ru) 2014-12-10
US20110182903A1 (en) 2011-07-28
EP2288387A1 (en) 2011-03-02
BRPI0913577A2 (pt) 2020-08-18
MX2010012576A (es) 2011-04-05
IL209207A0 (en) 2011-01-31
IL209207A (en) 2014-05-28
AU2009249540B2 (en) 2014-07-03
WO2009142759A1 (en) 2009-11-26
KR101679084B1 (ko) 2016-11-24
CN102036690A (zh) 2011-04-27

Similar Documents

Publication Publication Date Title
KR101679084B1 (ko) 신규 가용성 ｃｄ83 폴리펩티드, 제형 및 사용 방법
US20230158109A1 (en) Use of cd83 in combination therapies
EP1525221A1 (en) Conjugate of notch signalling pathway modulators and their use in medical treatment
JP2005505293A (ja) 修飾したヒト胸腺ストローマ細胞リンホポエチン
WO2022050401A2 (en) Interleukin-2 muteins and uses thereof
HK1155066B (en) Novel soluble cd83 polypeptides, formulations and methods of use
HK1203078B (en) Use of soluble cd83 for perfusing a tissue for transplantation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140319

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140919